Skip to main
MNKD
MNKD logo

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp is positioned for significant growth due to the potential approval of the Furoscix auto-injector, which may strengthen its product portfolio. The expectation of expanded labeling opportunities for the Tyvaso DPI, particularly in the context of treating pulmonary arterial hypertension (PAH), could further enhance the company's market presence and performance. Additionally, the strategic acquisition of SCPH is anticipated to bolster confidence in MannKind's capital allocation and may lead to higher peak sales forecasts, especially as interest in addressing patient needs outside of hospital settings grows.

Bears say

MannKind Corp's stock experienced significant weakness, declining 15.2%, likely due to the announcement of a competitive product from SQ Innovation priced at approximately 50% of MannKind's Furoscix, highlighting challenges in maintaining market share. Future sales projections for Afrezza are cautious, with estimates suggesting $127 million by 2030, contingent on successful market penetration, especially in the pediatric segment. Additionally, the company's pipeline assets MNKD-101 and MNKD-201 carry low probabilities of success (40% and 30%, respectively), reflecting inherent uncertainties in their development and commercialization strategies.

MannKind (MNKD) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 5 analysts, MannKind (MNKD) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.